JP2005508972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508972A5 JP2005508972A5 JP2003538142A JP2003538142A JP2005508972A5 JP 2005508972 A5 JP2005508972 A5 JP 2005508972A5 JP 2003538142 A JP2003538142 A JP 2003538142A JP 2003538142 A JP2003538142 A JP 2003538142A JP 2005508972 A5 JP2005508972 A5 JP 2005508972A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- imidazol
- iodo
- ylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 72
- 125000001072 heteroaryl group Chemical group 0.000 claims 38
- 229910052799 carbon Inorganic materials 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 36
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 125000003118 aryl group Chemical group 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000004404 heteroalkyl group Chemical group 0.000 claims 11
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims 11
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 125000002723 alicyclic group Chemical group 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000006413 ring segment Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- -1 1-imidazol-1-ylmethyl Chemical group 0.000 claims 3
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000005107 Premature Birth Diseases 0.000 claims 2
- 206010036590 Premature baby Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000001848 dysentery Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 201000011066 hemangioma Diseases 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 208000018875 hypoxemia Diseases 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- UHZIEFLWILBLGZ-UHFFFAOYSA-N (1-imidazol-1-yl-3-methoxypropan-2-yl) 4-iodobenzoate Chemical compound C=1C=C(I)C=CC=1C(=O)OC(COC)CN1C=CN=C1 UHZIEFLWILBLGZ-UHFFFAOYSA-N 0.000 claims 1
- CVSDGUSPTSMQBJ-UHFFFAOYSA-N (1-imidazol-1-yl-3-phenoxypropan-2-yl) 3-methoxybenzoate Chemical compound COC1=CC=CC(C(=O)OC(COC=2C=CC=CC=2)CN2C=NC=C2)=C1 CVSDGUSPTSMQBJ-UHFFFAOYSA-N 0.000 claims 1
- WXGSSMRODDWZFH-UHFFFAOYSA-N (1-imidazol-1-yl-3-phenoxypropan-2-yl) 4-(trifluoromethyl)benzoate Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)OC(CN1C=NC=C1)COC1=CC=CC=C1 WXGSSMRODDWZFH-UHFFFAOYSA-N 0.000 claims 1
- FULGRUKJYJWJDF-UHFFFAOYSA-N (1-imidazol-1-yl-3-phenoxypropan-2-yl) 4-bromo-2-chlorobenzoate Chemical compound ClC1=CC(Br)=CC=C1C(=O)OC(CN1C=NC=C1)COC1=CC=CC=C1 FULGRUKJYJWJDF-UHFFFAOYSA-N 0.000 claims 1
- FCNIAPWYVGTYIT-UHFFFAOYSA-N (1-imidazol-1-yl-3-phenoxypropan-2-yl) 4-bromobenzoate Chemical compound C1=CC(Br)=CC=C1C(=O)OC(CN1C=NC=C1)COC1=CC=CC=C1 FCNIAPWYVGTYIT-UHFFFAOYSA-N 0.000 claims 1
- ZRFIFBBEQSGQFS-UHFFFAOYSA-N (1-imidazol-1-yl-3-phenoxypropan-2-yl) 4-fluorobenzoate Chemical compound C1=CC(F)=CC=C1C(=O)OC(CN1C=NC=C1)COC1=CC=CC=C1 ZRFIFBBEQSGQFS-UHFFFAOYSA-N 0.000 claims 1
- QQRKJVIRHXDXHB-UHFFFAOYSA-N (1-imidazol-1-yl-3-phenoxypropan-2-yl) 4-methoxybenzoate Chemical compound C1=CC(OC)=CC=C1C(=O)OC(CN1C=NC=C1)COC1=CC=CC=C1 QQRKJVIRHXDXHB-UHFFFAOYSA-N 0.000 claims 1
- SJCCMELPLHYEQU-UHFFFAOYSA-N (1-imidazol-1-yl-3-phenoxypropan-2-yl) benzoate Chemical compound C=1C=CC=CC=1C(=O)OC(CN1C=NC=C1)COC1=CC=CC=C1 SJCCMELPLHYEQU-UHFFFAOYSA-N 0.000 claims 1
- CTQRYNQVNOXJOQ-UHFFFAOYSA-N (1-imidazol-1-yl-3-pyridin-3-yloxypropan-2-yl) 4-iodobenzoate Chemical compound C1=CC(I)=CC=C1C(=O)OC(CN1C=NC=C1)COC1=CC=CN=C1 CTQRYNQVNOXJOQ-UHFFFAOYSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 1
- HJMOACBJSLAGME-UHFFFAOYSA-N 2-chloro-n-(1-imidazol-1-yl-3-pyridin-3-yloxypropan-2-yl)-4-iodobenzamide Chemical compound ClC1=CC(I)=CC=C1C(=O)NC(CN1C=NC=C1)COC1=CC=CN=C1 HJMOACBJSLAGME-UHFFFAOYSA-N 0.000 claims 1
- DKDCTJRPQBGCFM-UHFFFAOYSA-N 2-chloro-n-[1-(4-fluorophenoxy)-3-imidazol-1-ylpropan-2-yl]-4-iodobenzamide Chemical compound C1=CC(F)=CC=C1OCC(NC(=O)C=1C(=CC(I)=CC=1)Cl)CN1C=NC=C1 DKDCTJRPQBGCFM-UHFFFAOYSA-N 0.000 claims 1
- AQABPIBXKWPEIJ-UHFFFAOYSA-N [1-(2-methylimidazol-1-yl)-3-(oxan-2-yloxy)propan-2-yl] 4-iodobenzoate Chemical compound CC1=NC=CN1CC(OC(=O)C=1C=CC(I)=CC=1)COC1OCCCC1 AQABPIBXKWPEIJ-UHFFFAOYSA-N 0.000 claims 1
- VTSBOMMVBCCYNZ-UHFFFAOYSA-N [1-(4-acetamidophenoxy)-3-imidazol-1-ylpropan-2-yl] 4-iodobenzoate Chemical compound C1=CC(NC(=O)C)=CC=C1OCC(OC(=O)C=1C=CC(I)=CC=1)CN1C=NC=C1 VTSBOMMVBCCYNZ-UHFFFAOYSA-N 0.000 claims 1
- DKQCXNIDGIPIBX-UHFFFAOYSA-N [1-(4-cyanophenoxy)-3-(2-methylimidazol-1-yl)propan-2-yl] 4-iodobenzoate Chemical compound CC1=NC=CN1CC(OC(=O)C=1C=CC(I)=CC=1)COC1=CC=C(C#N)C=C1 DKQCXNIDGIPIBX-UHFFFAOYSA-N 0.000 claims 1
- GVKYQAMIWRBSJC-UHFFFAOYSA-N [1-(4-cyanophenoxy)-3-imidazol-1-ylpropan-2-yl] 4-iodobenzoate Chemical compound C1=CC(I)=CC=C1C(=O)OC(CN1C=NC=C1)COC1=CC=C(C#N)C=C1 GVKYQAMIWRBSJC-UHFFFAOYSA-N 0.000 claims 1
- JTNXYKMQMWRALS-UHFFFAOYSA-N [1-(4-fluorophenoxy)-3-(1,2,4-triazol-1-yl)propan-2-yl] 4-iodobenzoate Chemical compound C1=CC(F)=CC=C1OCC(OC(=O)C=1C=CC(I)=CC=1)CN1N=CN=C1 JTNXYKMQMWRALS-UHFFFAOYSA-N 0.000 claims 1
- MYYLIMLHXIIIMZ-UHFFFAOYSA-N [1-(4-fluorophenoxy)-3-imidazol-1-ylpropan-2-yl] 2,4-dichlorobenzoate Chemical compound C1=CC(F)=CC=C1OCC(OC(=O)C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MYYLIMLHXIIIMZ-UHFFFAOYSA-N 0.000 claims 1
- SGWCLRZNWVPFJX-UHFFFAOYSA-N [1-(4-fluorophenoxy)-3-imidazol-1-ylpropan-2-yl] 4-iodobenzoate Chemical compound C1=CC(F)=CC=C1OCC(OC(=O)C=1C=CC(I)=CC=1)CN1C=NC=C1 SGWCLRZNWVPFJX-UHFFFAOYSA-N 0.000 claims 1
- VUIUMNPJDNTIKP-UHFFFAOYSA-N [1-(4-fluorophenoxy)-3-imidazol-1-ylpropan-2-yl] 4-methoxybenzoate Chemical compound C1=CC(OC)=CC=C1C(=O)OC(CN1C=NC=C1)COC1=CC=C(F)C=C1 VUIUMNPJDNTIKP-UHFFFAOYSA-N 0.000 claims 1
- ZQSZSWQNEFVKGG-UHFFFAOYSA-N [1-(cyclopropylmethoxy)-3-(2-methylimidazol-1-yl)propan-2-yl] 2-chloro-4-iodobenzoate Chemical compound CC1=NC=CN1CC(OC(=O)C=1C(=CC(I)=CC=1)Cl)COCC1CC1 ZQSZSWQNEFVKGG-UHFFFAOYSA-N 0.000 claims 1
- GUUSBVNDBCVAIS-UHFFFAOYSA-N [1-imidazol-1-yl-3-(2-nitrophenoxy)propan-2-yl] 4-iodobenzoate Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC(OC(=O)C=1C=CC(I)=CC=1)CN1C=NC=C1 GUUSBVNDBCVAIS-UHFFFAOYSA-N 0.000 claims 1
- YOPNHJJETCAFCE-UHFFFAOYSA-N [1-imidazol-1-yl-3-(3-nitrophenoxy)propan-2-yl] 4-iodobenzoate Chemical compound [O-][N+](=O)C1=CC=CC(OCC(CN2C=NC=C2)OC(=O)C=2C=CC(I)=CC=2)=C1 YOPNHJJETCAFCE-UHFFFAOYSA-N 0.000 claims 1
- XCWWZSYUAYVVMT-UHFFFAOYSA-N [1-imidazol-1-yl-3-(4-iodophenoxy)propan-2-yl] 4-bromo-2-chlorobenzoate Chemical compound C1=CC(=CC=C1OCC(CN2C=CN=C2)OC(=O)C3=C(C=C(C=C3)Br)Cl)I XCWWZSYUAYVVMT-UHFFFAOYSA-N 0.000 claims 1
- CCKLUXJAXAWORF-UHFFFAOYSA-N [1-imidazol-1-yl-3-(4-iodophenoxy)propan-2-yl] 4-iodobenzoate Chemical compound C1=CC(I)=CC=C1OCC(OC(=O)C=1C=CC(I)=CC=1)CN1C=NC=C1 CCKLUXJAXAWORF-UHFFFAOYSA-N 0.000 claims 1
- LZBOKYSSRYQASV-UHFFFAOYSA-N [1-imidazol-1-yl-3-(4-iodophenoxy)propan-2-yl] 4-methoxybenzoate Chemical compound COC1=CC=C(C=C1)C(=O)OC(CN2C=CN=C2)COC3=CC=C(C=C3)I LZBOKYSSRYQASV-UHFFFAOYSA-N 0.000 claims 1
- DPTLLKCIWYDYRY-UHFFFAOYSA-N [1-imidazol-1-yl-3-(4-methoxyphenoxy)propan-2-yl] 4-methoxybenzoate Chemical compound C1=CC(OC)=CC=C1OCC(OC(=O)C=1C=CC(OC)=CC=1)CN1C=NC=C1 DPTLLKCIWYDYRY-UHFFFAOYSA-N 0.000 claims 1
- JTWITXSRBQCTHA-UHFFFAOYSA-N [1-imidazol-1-yl-3-(4-nitrophenoxy)propan-2-yl] 4-iodobenzoate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCC(OC(=O)C=1C=CC(I)=CC=1)CN1C=NC=C1 JTWITXSRBQCTHA-UHFFFAOYSA-N 0.000 claims 1
- DRHNPUWRASFLHB-UHFFFAOYSA-N [3-imidazol-1-yl-2-(4-iodobenzoyl)oxy-2-methylpropyl] 4-nitrobenzoate Chemical compound C1=CN=CN1CC(OC(=O)C=1C=CC(I)=CC=1)(C)COC(=O)C1=CC=C([N+]([O-])=O)C=C1 DRHNPUWRASFLHB-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- DLSUFMMWXXPUHP-UHFFFAOYSA-N n-(1-imidazol-1-yl-3-phenoxypropan-2-yl)-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NC(CN1C=NC=C1)COC1=CC=CC=C1 DLSUFMMWXXPUHP-UHFFFAOYSA-N 0.000 claims 1
- QAWIWTFXLCFEOO-UHFFFAOYSA-N n-(1-imidazol-1-yl-3-pyridin-3-yloxypropan-2-yl)-4-iodobenzamide Chemical compound C1=CC(I)=CC=C1C(=O)NC(CN1C=NC=C1)COC1=CC=CN=C1 QAWIWTFXLCFEOO-UHFFFAOYSA-N 0.000 claims 1
- SVOVZDKVCARNGV-UHFFFAOYSA-N n-(3-imidazol-1-yl-2-phenoxypropyl)-4-iodo-n-methylbenzamide Chemical compound C=1C=C(I)C=CC=1C(=O)N(C)CC(OC=1C=CC=CC=1)CN1C=CN=C1 SVOVZDKVCARNGV-UHFFFAOYSA-N 0.000 claims 1
- IQBUWEXLNJURKA-UHFFFAOYSA-N n-[1-(2-chloroimidazol-1-yl)-3-(4-cyanophenoxy)propan-2-yl]-4-iodobenzamide Chemical compound ClC1=NC=CN1CC(NC(=O)C=1C=CC(I)=CC=1)COC1=CC=C(C#N)C=C1 IQBUWEXLNJURKA-UHFFFAOYSA-N 0.000 claims 1
- ZBIMAVFHIWZMKT-UHFFFAOYSA-N n-[1-(2-chloroimidazol-1-yl)-3-(4-fluorophenoxy)propan-2-yl]-4-iodobenzamide Chemical compound C1=CC(F)=CC=C1OCC(NC(=O)C=1C=CC(I)=CC=1)CN1C(Cl)=NC=C1 ZBIMAVFHIWZMKT-UHFFFAOYSA-N 0.000 claims 1
- QFSOXHYEFJFLIL-UHFFFAOYSA-N n-[1-(3-cyanopyridin-2-yl)oxy-3-imidazol-1-ylpropan-2-yl]-4-iodobenzamide Chemical compound C1=CC(I)=CC=C1C(=O)NC(CN1C=NC=C1)COC1=NC=CC=C1C#N QFSOXHYEFJFLIL-UHFFFAOYSA-N 0.000 claims 1
- AQPCOTGUGIETJG-UHFFFAOYSA-N n-[1-(4-cyanophenoxy)-3-(2-methylimidazol-1-yl)propan-2-yl]-4-iodobenzamide Chemical compound CC1=NC=CN1CC(NC(=O)C=1C=CC(I)=CC=1)COC1=CC=C(C#N)C=C1 AQPCOTGUGIETJG-UHFFFAOYSA-N 0.000 claims 1
- VNJZUFANCKZCQJ-UHFFFAOYSA-N n-[1-(4-cyanophenoxy)-3-imidazol-1-ylpropan-2-yl]-4-iodobenzamide Chemical compound C1=CC(I)=CC=C1C(=O)NC(CN1C=NC=C1)COC1=CC=C(C#N)C=C1 VNJZUFANCKZCQJ-UHFFFAOYSA-N 0.000 claims 1
- NCRBSVCFQVEWOV-UHFFFAOYSA-N n-[1-(4-fluorophenoxy)-3-(1,2,4-triazol-1-yl)propan-2-yl]-4-iodobenzamide Chemical compound C1=CC(F)=CC=C1OCC(NC(=O)C=1C=CC(I)=CC=1)CN1N=CN=C1 NCRBSVCFQVEWOV-UHFFFAOYSA-N 0.000 claims 1
- QLLXRCLKWKJALI-UHFFFAOYSA-N n-[1-(4-fluorophenoxy)-3-(2-phenylimidazol-1-yl)propan-2-yl]-4-iodobenzamide Chemical compound C1=CC(F)=CC=C1OCC(NC(=O)C=1C=CC(I)=CC=1)CN1C(C=2C=CC=CC=2)=NC=C1 QLLXRCLKWKJALI-UHFFFAOYSA-N 0.000 claims 1
- FDVQXBWOPAKJQL-UHFFFAOYSA-N n-[1-(4-fluorophenoxy)-3-(tetrazol-1-yl)propan-2-yl]-4-iodobenzamide Chemical compound C1=CC(F)=CC=C1OCC(NC(=O)C=1C=CC(I)=CC=1)CN1N=NN=C1 FDVQXBWOPAKJQL-UHFFFAOYSA-N 0.000 claims 1
- KQZATCYBCYMUDZ-UHFFFAOYSA-N n-[1-(4-fluorophenoxy)-3-imidazol-1-ylpropan-2-yl]-3-iodobenzamide Chemical compound C1=CC(F)=CC=C1OCC(NC(=O)C=1C=C(I)C=CC=1)CN1C=NC=C1 KQZATCYBCYMUDZ-UHFFFAOYSA-N 0.000 claims 1
- YKSRQAMHHKDSQI-UHFFFAOYSA-N n-[1-(4-fluorophenoxy)-3-imidazol-1-ylpropan-2-yl]-4-iodobenzamide Chemical compound C1=CC(F)=CC=C1OCC(NC(=O)C=1C=CC(I)=CC=1)CN1C=NC=C1 YKSRQAMHHKDSQI-UHFFFAOYSA-N 0.000 claims 1
- HWDXDASZYYWECJ-UHFFFAOYSA-N n-[1-(4-tert-butylphenoxy)-3-imidazol-1-ylpropan-2-yl]-4-iodobenzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1OCC(NC(=O)C=1C=CC(I)=CC=1)CN1C=NC=C1 HWDXDASZYYWECJ-UHFFFAOYSA-N 0.000 claims 1
- ASKHKPOODHCNAG-UHFFFAOYSA-N n-[1-(5-cyanopyridin-2-yl)oxy-3-imidazol-1-ylpropan-2-yl]-4-iodobenzamide Chemical compound C1=CC(I)=CC=C1C(=O)NC(CN1C=NC=C1)COC1=CC=C(C#N)C=N1 ASKHKPOODHCNAG-UHFFFAOYSA-N 0.000 claims 1
- GCMCUFFVCDXDEZ-UHFFFAOYSA-N n-[1-[2-(difluoromethyl)imidazol-1-yl]-3-(4-fluorophenoxy)propan-2-yl]-4-iodobenzamide Chemical compound FC(F)C1=NC=CN1CC(NC(=O)C=1C=CC(I)=CC=1)COC1=CC=C(F)C=C1 GCMCUFFVCDXDEZ-UHFFFAOYSA-N 0.000 claims 1
- WRRJDCHXJQQHLW-UHFFFAOYSA-N n-[1-imidazol-1-yl-3-(3-nitropyridin-2-yl)oxypropan-2-yl]-4-iodobenzamide Chemical compound [O-][N+](=O)C1=CC=CN=C1OCC(NC(=O)C=1C=CC(I)=CC=1)CN1C=NC=C1 WRRJDCHXJQQHLW-UHFFFAOYSA-N 0.000 claims 1
- VDXFXTGIYZVGPA-UHFFFAOYSA-N n-[1-imidazol-1-yl-3-(4-nitrophenoxy)propan-2-yl]-4-iodobenzamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCC(NC(=O)C=1C=CC(I)=CC=1)CN1C=NC=C1 VDXFXTGIYZVGPA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33604001P | 2001-10-23 | 2001-10-23 | |
| PCT/US2002/033963 WO2003035626A2 (en) | 2001-10-23 | 2002-10-23 | Azole derivatives and pharmaceutical compositions containing them |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005508972A JP2005508972A (ja) | 2005-04-07 |
| JP2005508972A5 true JP2005508972A5 (enExample) | 2006-01-05 |
| JP4602667B2 JP4602667B2 (ja) | 2010-12-22 |
Family
ID=23314305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003538142A Expired - Fee Related JP4602667B2 (ja) | 2001-10-23 | 2002-10-23 | アゾール誘導体および該アゾール誘導体を含有する医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7253199B2 (enExample) |
| EP (2) | EP1438295B1 (enExample) |
| JP (1) | JP4602667B2 (enExample) |
| AU (2) | AU2002359291C1 (enExample) |
| CA (1) | CA2463101A1 (enExample) |
| ES (1) | ES2393186T3 (enExample) |
| IL (1) | IL161580A0 (enExample) |
| WO (1) | WO2003035626A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7253199B2 (en) * | 2001-10-23 | 2007-08-07 | Applied Research Systems Ars Holding N.V. | Azole derivatives and pharmaceutical compositions containing them |
| AR051248A1 (es) | 2004-10-20 | 2007-01-03 | Applied Research Systems | Derivados de 3-arilamino piridina |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| ES2353437T3 (es) | 2006-02-16 | 2011-03-02 | Schering Corporation | Derivados de pirrolidina como inhibidores de erk. |
| SG188179A1 (en) | 2008-02-21 | 2013-03-28 | Merck Sharp & Dohme | Compounds that are erk inhibitors |
| US8951979B2 (en) * | 2008-06-13 | 2015-02-10 | Cornell University | Pain treatment using ERK2 inhibitors |
| WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
| WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| US8962606B2 (en) | 2009-10-21 | 2015-02-24 | Bayer Intellectual Property Gmbh | Substituted benzosulphonamides |
| CA2777071A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
| CA2777430A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| AU2011224410B2 (en) | 2010-03-09 | 2015-05-28 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| US9045429B2 (en) | 2010-10-29 | 2015-06-02 | Bayer Intellectual Property Gmbh | Substituted phenoxypyridines |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| EP3355923B1 (en) | 2015-10-01 | 2022-02-23 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma |
| WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
| WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
| WO2021018866A1 (en) * | 2019-07-30 | 2021-02-04 | Edvince Ab | Mek inhibitor for treatment of stroke |
| CN110845703A (zh) * | 2019-10-28 | 2020-02-28 | 上海瀚岱化学有限公司 | 一种水性环氧树脂及其制备方法 |
| CN110903735A (zh) * | 2019-11-11 | 2020-03-24 | 上海瀚岱化学有限公司 | 一种水性环氧涂料及其制备方法与应用 |
| EP4142878B1 (en) | 2020-04-28 | 2024-06-26 | The Regents of The University of Michigan | Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same |
| CN112759742A (zh) * | 2020-12-18 | 2021-05-07 | 江西瀚泰新材料科技有限公司 | 一种增韧型水性环氧树脂及其制备方法 |
| CN112794989A (zh) * | 2020-12-18 | 2021-05-14 | 江西瀚泰新材料科技有限公司 | 一种增韧阻燃水性环氧树脂及其制备方法 |
| CN112646123A (zh) * | 2020-12-18 | 2021-04-13 | 江西瀚泰新材料科技有限公司 | 一种低粘度水性环氧树脂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1271477A (en) * | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| PL195600B1 (pl) * | 1998-05-15 | 2007-10-31 | Astrazeneca Ab | Pochodne benzamidowe, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie do wytwarzania leku do leczenia stanów medycznych powstających za pośrednictwem cytokin |
| US6599910B1 (en) * | 1998-08-20 | 2003-07-29 | Smithkline Beecham Corporation | Substituted triazole compounds |
| AP2001002225A0 (en) * | 1999-01-13 | 2001-09-30 | Warner Lambert Co | 1-heterocycle substituted diarylamines. |
| US7253199B2 (en) * | 2001-10-23 | 2007-08-07 | Applied Research Systems Ars Holding N.V. | Azole derivatives and pharmaceutical compositions containing them |
-
2002
- 2002-10-23 US US10/491,902 patent/US7253199B2/en not_active Expired - Fee Related
- 2002-10-23 ES ES02793814T patent/ES2393186T3/es not_active Expired - Lifetime
- 2002-10-23 JP JP2003538142A patent/JP4602667B2/ja not_active Expired - Fee Related
- 2002-10-23 WO PCT/US2002/033963 patent/WO2003035626A2/en not_active Ceased
- 2002-10-23 AU AU2002359291A patent/AU2002359291C1/en not_active Ceased
- 2002-10-23 CA CA002463101A patent/CA2463101A1/en not_active Abandoned
- 2002-10-23 EP EP02793814A patent/EP1438295B1/en not_active Expired - Lifetime
- 2002-10-23 IL IL16158002A patent/IL161580A0/xx unknown
- 2002-10-23 EP EP10075495A patent/EP2332922A1/en not_active Withdrawn
-
2007
- 2007-07-24 US US11/782,251 patent/US7541375B2/en not_active Expired - Fee Related
-
2008
- 2008-06-20 AU AU2008202731A patent/AU2008202731A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508972A5 (enExample) | ||
| KR101502959B1 (ko) | 5원환 헤테로환 유도체 및 그 의약 용도 | |
| ES2393186T3 (es) | Derivados de azol y composiciones farmacéuticas que los contienen | |
| Trivedi et al. | Supramolecular assemblies in salts and co-crystals of imidazoles with dicarboxylic acids | |
| US20130289280A1 (en) | Novel pharmaceutical forms, and methods of making and using the same | |
| WO2003074474A2 (en) | Multiple-component solid phases containing at least one active pharmaceutical ingredient | |
| EA009985B1 (ru) | Новый способ получения рофлумиласта | |
| JP2010518067A (ja) | 抗寄生虫剤 | |
| JP2018520205A (ja) | レンバチニブメシル酸塩の新規結晶形及びその製造方法 | |
| RU2005123802A (ru) | Производные адамантана, способы их получения и содержащие их фармацевтические композиции | |
| JP2004525127A (ja) | バニロイド受容体（ｖｒ１）アンタゴニスト活性を有する尿素誘導体 | |
| AU2002359291A1 (en) | Azole derivatives and pharmaceutical compositions containing them | |
| DE69620582T2 (de) | Verwendung von WISMUTVERBINDUNGEN zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden | |
| JP2010522710A (ja) | Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体 | |
| RU2700796C2 (ru) | Синтез и новые солевые формы (r)-5-((е)-2-пирролидин-3-илвинил)пиримидина | |
| JP2007522135A5 (enExample) | ||
| RU2002113759A (ru) | Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII | |
| AU2018378348B2 (en) | Crystal forms and production methods thereof | |
| JP2009040767A5 (enExample) | ||
| DE68911699T2 (de) | Diamin-Verbindungen. | |
| NO20022919L (no) | Nye forbindelser | |
| RU2011101661A (ru) | Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний | |
| JP2008534534A5 (enExample) | ||
| HRP20210211T1 (hr) | Triazoli namijenjeni reguliranju homeostaze unutarstaničnog kalcija | |
| JP2010528088A5 (enExample) |